-
EP2407152
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2407152
| EP2407152 - Formulations of 14-epi-analogues of vitamin D [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 14.12.2012 Database last updated on 20.05.2024 | Most recent event Tooltip | 14.12.2012 | Application deemed to be withdrawn | published on 16.01.2013 [2013/03] | Applicant(s) | For all designated states Hybrigenics S.A. 3/5, Impasse Reille 75014 Paris / FR | [2012/03] | Inventor(s) | 01 /
Delansorne, Rémi 30, rue Guynemer 75006, PARIS / FR | [2012/03] | Representative(s) | Blot, Philippe Robert Emile Cabinet Lavoix 2, Place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | [N/P] |
| Former [2012/03] | Blot, Philippe Robert Emile Cabinet Lavoix 2, place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | Application number, filing date | 10305783.2 | 15.07.2010 | [2012/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2407152 | Date: | 18.01.2012 | Language: | EN | [2012/03] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.07.2011 | Classification | IPC: | A61K9/10, A61K9/20, A61K9/00, A61K9/48, A61K47/10 | [2012/03] | CPC: |
A61K47/10 (EP);
A61K9/0095 (EP);
A61K9/10 (EP);
A61K9/2054 (EP);
A61K9/4858 (EP);
A61P19/10 (EP);
A61P3/10 (EP);
A61P3/14 (EP);
A61P43/00 (EP);
A61P9/00 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/03] | Extension states | BA | Not yet paid | ME | Not yet paid | RS | Not yet paid | Title | German: | Formulierungen von 14-epi-Analoga von Vitamin D | [2012/03] | English: | Formulations of 14-epi-analogues of vitamin D | [2012/03] | French: | Formulations de 14-épi-analogues de la vitamine D | [2012/03] | Examination procedure | 19.07.2012 | Application deemed to be withdrawn, date of legal effect [2013/03] | 30.08.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2013/03] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.07.2012 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO2006042383 (LEUVEN K U RES & DEV [BE], et al) [X] 1,3,11-14 * example 3 * [Y] 1,3-14; | [XY]JP2010111593 (TEIJIN PHARMA LTD) [X] 1,3,11,12,14 * claims 1-9 * * paragraph [0041] * [Y] 1,3-14; | [Y]US2007093458 (SCHWARTZ ANCHEL [IL], et al) [Y] 1,3-14 * page 4, paragraph 66 - page 6, paragraph 87 * * claims 1-53 *; | [E]EP2263677 (HYBRIGENICS SA [FR]) [E] 1,3,10-14 * example 1 * * paragraph [0033] - paragraph [0035] *; | [XY] - "Promising interim results from Hybrigenics' Inecalcitol Phase II in combination with Taxotere(R) for hormone refractory prostate cancer", INTERNET CITATION, (20090419), pages 1 - 3, URL: http://www.medicalnewstoday.com/articles/146552.php, (20100708), XP002592440 [X] 1,3,10-14 * the whole document * [Y] 1,3-14 | [Y] - MANUS ET AL, "Inecalcitol, traitement du cancer de la prostate", REVUE FRANCOPHONE DES LABORATOIRES, ELSEVIER, AMSTERDAM, NL, vol. 2008, no. 405, doi:10.1016/S1773-035X(08)74264-3, ISSN 1773-035X, (20081001), page 12, (20081001), XP025686090 [Y] 1,3-14 * the whole document * DOI: http://dx.doi.org/10.1016/S1773-035X(08)74264-3 | [Y] - STRICKLEY R G, "SOLUBILIZING EXCIPIENTS IN ORAL AND INJECTABLE FORMULATIONS", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, (20040201), vol. 21, no. 2, doi:10.1023/B:PHAM.0000016235.32639.23, ISSN 0724-8741, pages 201 - 230, XP009035738 [Y] 1,3,6-14 * page 203; table I * * last paragraph; page 207 * * table II * DOI: http://dx.doi.org/10.1023/B:PHAM.0000016235.32639.23 | by applicant | US7332482 | EP0707566 | WO2004080922 | US5936105 | WO9501960 | - HOLUMBERG ET AL., BIOPHARM. DRUG DISP., (1990), vol. 11, pages 807 - 8015 | - GROVE ET AL., J. PHARM. SCI., (2005), vol. 8, pages 1830 - 1838 | - PORTER ET AL., NATURE REV. DRUG DISCOVERY, (2007), vol. 6, pages 231 - 248 | - GROVE ET AL., EUR. J. PHARMA. SCI., (2006), vol. 28, pages 233 - 242 | - EELEN ET AL., MOLECULAR PHARMACOLOGY, (2005), vol. 67, pages 1566 - 1573 | - VERLINDEN ET AL., JOURNAL OF BONE AND MINERAL RESEARCH, (2001), vol. 16, no. 4, pages 625 - 638 | - VERLINDEN ET AL., CANCER RES., (2000), vol. 60, pages 2673 - 2679 | - MAYNARD ET AL., J. MED. CHEM., (1994), vol. 37, pages 2387 - 2393 | - SAWADA ET AL., BIOORG. MED. CHEM., (2009), vol. 19, pages 5397 - 5400 | - SAWADA ET AL., CHEM. PHARM. BULL, (2009), vol. 57, pages 1431 - 1433 | - KITTAKA ET AL., ANTICANCER RES., (2009), vol. 9, pages 3563 - 3569 |